V 21. století budeme bez zácpy(Zácpa je syndrom nízkého serotoninu)

English version

Autoři: Z. Bic ^1,2,3; S. Bizal ^3,4
Působiště autorů: Department of Population Health and Disease Prevention, Public Health Program, College of Health Sciences, University of California, Irvine, USA http://www. cohs. uci. edu/publichealth/ ¹; The American College of Lifestyle Medicine, www. lifestylemedicine. org ²; Wellness Coaching Institute, USA www. wellnesscoachinginstitute. com ³; The Bizal Group, Inc., USA ⁴
Vyšlo v časopise: Gastroent Hepatol 2010; 64(4): 10-17
Kategorie: Původní práce

Souhrn

Zácpa je častý syndrom postihující miliony lidí – syndrom, který se brání definitivní léčbě, způsobuje miliony ročních návštěv lékařů, za léky bez lékařského předpisu se za ni utratí miliony dolarů ročně, je provázena ekonomickými následky pro komunitu i jedince a sníženou kvalitou života. Hypotéza: Může vhodná aplikace wellness a změny životního stylu snížit riziko vzniku zácpy, změnit již přítomnou zácpu a zlepšit kvalitu života? Metoda: Vyšetřili jsme problematiku zácpy z hlediska veřejného zdraví ve 21. století. Prohlédli jsme recentní literaturu o zácpě z hlediska epidemiologie, statistiky, ekonomických následků, geografické polohy, pohlaví, socioekonomické situace, úrovně vzdělání a zdravotnické osvěty, stravovacích návyků, fyzické aktivity, úrovně stresu, komorbidity, užívaných léků a základních přírodních principů. Dva recenzenti provedli hledání citací ve Scholar Google a na Medline. Výsledky: Vyvinuli jsme teoretický model zácpy – problém veřejného zdraví ve 21. století z hlediska rizikových faktorů, prevence, léčby a aplikace medicíny wellness/změna životního stylu (tab. 1). Závěry: Zácpu je třeba zkoumat z různých hledisek. Pro prevenci a léčbu zácpy doporučujeme nový styl wellness/změnu životního stylu. Je nezbytné, aby poskytovatelé léčebné péče začali aplikovat tento postoj do svého lékařského modelu léčby. Také navrhujeme, aby zácpa nebyla považována za samostatný syndrom, ale jako první signál potenciálního porušení biochemické tělesné rovnováhy, který může vést k vývoji chronických onemocnění.

Klíčová slova:
zácpa – serotonin – životní styl – wellness – výživa – fyzická aktivita – stres

Zdroje

1. Thompson W, Longstreth G, Drossman D. Functional bowel disorders and functional abdominal pain. Gut 1999; 45: 43–47.

2. Peppas G, Alexious VG, Mourtzoukou E et al. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterology 2008, 8: 5.

3. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99(4): 750–759.

4. Curry CE. Laxatives. In: Handook of non-prescription Drugs, 8th Ed.Washington, DC:American Pharmaceutical Association, 1986: 75–97.

5. Stewart WF, Liberman JN, Sandler RS et al. Epidemiology of constipation (EPOC) study in United States: Relation of clinical subtypes to socio-demographic features. Am J Gastroenterol 1999; 94(12): 3530–3540.

6. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 1989; 34(4): 606–611.

7. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol 1989; 11(5): 525–536.

8. Irvine EJ, Ferrazzi S, Pare P et al. Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol 2002; 97(8): 1986–1993.

9. Hammond E. Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Pub health 1964; 54: 11–23.

10. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. Am J Public Health 1990; 80(2): 185–189.

11. Johanson JF. Geographic distribution of constipation in the United States. Am J Gastroenterol 1998; 93(2): 188–191.

12. Battle WM, Sanppe WJ, Alavi A et al. Colonic dysfunction in diabetes mellitus. Gastroenterology 1980; 79(6): 1217–1221.

13. Camilleri M. Gastrointestinal problems in Diabetes. Endocrinology & Metabolism Clinics of North America 1996; 25(2): 361–378.

14. Blazedr DG, Federspiel CF, Ray WA et al. Thenrisk of anticholinergic toxicity in then elederly – a study of prescribed practices in two populations. J Gerontol 1983; 38(1): 31–35.

15. Mintzer J, Burns A. Anticholinergic side-efects of drugs in elderly people. Journal of the Royal Socirty of Medicne 2000; 93(9): 457–462.

16. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci 1991; 36(1): 59–64.

17. El-Salhy M, Norrgĺrd O, Spinnell S. Abnormal Colonic Endocrine Cells in patients with chronic Idiopathic Slow-Transit constipation. Scandinavian Journal of Gastroenterology 1999; 34(10): 1007–1011.

18. Galisteo M, Duarte J, Zarzuelo A. Effects of dietary fibers on disturbances clustered in the metabolic syndrome. J Nutr Biochem 2009; 19(2): 71–84.

19. Lembo A, Camilleri M. Chronic Constipation. The New England Journal of Medicine 2003; 349(14): 1360–1368.

20. Hassler WL. Serotonin and GI tract. Curr Gastroenterol Rep 2009; 11(5): 383–391.

21. Tonini M, Pace F. Drugs acting on serotonin receptors for treatment of functional GI disorders. Dig Dis 2006; 24(1-2): 59–69.

22. Talley NJ. Definitions, epidemiology, and impact of chronic constipation. Rev Gastroenterol Disord 2004; Suppl 2: S3–S10.

23. Liu F, Kondo T, Toda Y. Brief physical inactivity prolongs colonic transit time in elderly active men. Int J Sports Med1993; 14(8): 465–467.

24. Muller-Lissner SA, Kamm MA, Scarpignato C et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100(1): 232–242.

25. Karam SE, Nies DM, student/staff collaboration. A pilot bowel management program. J Gerontol Nurs 1994; 20(3): 32–40.

26. Chan AO, Hui WM, HU WH et al. Differing coping mechanisms, stress level and anorectal physiology in patients with functional constipation. World J Gastroenterol 2005; 11(34): 5362–5366.

27. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 2009; 403(1-2): 47-55.

28. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. Am J Public Health 1990; 80(2): 185–189.

29. Ouwehand AC, Lagström H, Suomalainen T et al. Effect of Probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutri Metab 2002; 46(3–4): 159–162.

30. Wisten A, Messner T. Fruit and fibre (Pajal porridge) in the prevention of constipation. Scand J Caring Sci 2005; 19(1): 71–76.

31. Taylor R. Management of constipation:high fibre diet works. Br Med J 1990; 300(6731): 1063–104, 1990.

32. Lee WTK, Ip KS, Chan JSH et al. Increased prevalence of constipation in pre-school children is attributable to under-consumption of plant foods: a community-based study. J Pediatr Child Health 2008; 44: 170–175.

33. Castillejo G, Bullo M, Anguera A et al. A randomized double-blind trial to evaluate the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated pediatric patients. Pediatrics 2006; 118(3): e641–e648.

34. Haug TT, Mykletun A, Dahl AA. Are anxiety and depression related to gastrointestinal symptoms in the general population? Scand J Gastroenterol 2002; 37(3): 294–298.

35. Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. Dig Dis Sci 1987; 32(8): 841–845.

36. Herz MJ, Kahan E, Zalevski S et al. Constipation: a different entity for patients and doctors. Fam Pract 1996; 13(2): 156–159.

37. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97(Suppl): S1–S5.

38. Goldberg M et al. “In patients with chronic constipation, TD-5108, a selective 5-HT 4 agonist with high intrinsic activity, increases bowel movement frequency and the proportion of patients with adequate relief”. American College of Gastroenterology Annual Meeting and Postgraduate Course 2007; 12-17; Philadelphia, Abstract 56.

39. Johanson JF, Sonnenberg A, Koch TR. Clinical Epidemiology of chronic constipation. Journal of Clinical Gastroenterology 1989; 11(5): 525–536.

40. Siller R. Serotonergic agents and irritable bowle syndrome: what goes wrong? Curr Opin Pharmacol 2008; 8(6): 709–714.

41. Ducrotte P. Irritable bowel syndrome: current treatment options. Presse med 2007; 36(11 Pt 2): 1619–1626.

42. Tramer M. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: A quantitative systematic review. Eur J Cancer 2009; 34(12): 1836–1844.

43. Le Marchand L, Wilkens LR, Kolonel LN et al. Associations of sedentary liefestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 1997; 57(21): 4787-4794.

44. Camilleri M, Kerstens R, Rykx A et al. A pleacebocontrolled trial of Prucalopride for severe chronic constipation. N Engl J Med 2008; 358(22): 2344–2354.

45. Goadsby PJ. Serotonin 5 HT receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS drugs 1998; 10(4): 271–286.

46. Ferrari M, Roon K, Lipton R et al. Oral triptans (serotonin 5-HT agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358(9294): 1668–1675.

47. Harrington KL, Haskvitz EM. Managing a patient’s constipation with physical therapy. Phys Ther 2006; 86(11): 1511–1519.

48. Cummings JH. Constipation, dietary fibre and the control of large bowel function. Postgraduate Medical Journal 1984; 60(709): 811–819.

49. Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981; 16(9): 837–850.

50. Jagielska G, Tomaszewicz-Libudzic CA, Brzozowska A. Pellagra – a rare complication of anorexia nervosa. Eur Child Adolesc Psychiatry 2007; 16(7): 417–420.

51. Raghuram TC, Krishnaswarmy K. Serotonin metabolism in pellagra. Arch Neurol 1975; 32(10): 708–710.

52. Gershon JT. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132(1): 397–414.

53. Ginzburg R, Ambizas E. Clinical pharmavology of Lubiprostone, a chloride channel activator in defecation disorders. Expert Opin Drug MetabmToxicol 2008; 4(8): 1091–1097.

54. Phinney SD, Odin RS, Johnson SB et al. Reduced arachidonat in serum phospholipids and cholesteryl esters associated with vegetarian diets in humans. Am J Clin Nutr 1990; 51(3): 385–392.

55. Bic Z, Blix G, Hopp HP et al. In search of the ideal treatment for migraine headache. Medical Hypothesis 1998, 50(1), 1–7.

56. Bic Z, Blix G, Hopp HP et al. The influence of a low-fat diet on incidence and severity of migraine headaches. J Womens health Gend Based Med 1999; 8(5): 623–630.

57. Wurtman RJ, Wurtman JJ. “Nutrition and brain”. Disorders of eating and nutrients in treatment of brain disease. Raven Press. New York, edited by RJ Wurtman and J.J Wurtman. Volume 3.

58. Stein EA, Shapero J, McNerney C et al. Changes in plasma lipid and lipoprotein fractions after alteration in dietary cholesterol, polyunsaturated, saturated, and total fat in free-living normal and hypercholesterolemic children. Am J Clin Nutr 1982; 35(6): 1375–1390.

59. Nettleton JA. Omega-3 fatty acids: comparison of plant and seafood sources in human nutrition, J Am Diet Assoc 1991; 91(3): 331–337.

60. Raghuram TC, Krishnaswamy K. Serotonin Metabolism in Pellagra. Arch Neurol 1975; 32(10): 708–710.

61. Ishii N, Nishikara Y. Pellagra among chronic alcoholics: clinical and pathological study of 20 necropsy cases. J Neurol Neurosurg Psychiatry 1981; 44(3): 209–215.

62. Wegener M, Schaffstein J, Dilger U et al. Gastrointestinal transit of solid-liquid meal in chronic alcoholics. Dig Dis Sci 1991; 36(7): 917–923.

63. Rossignol AM. Caffeine containing beverages and premenstrual syndrome among young women. Am J Public Health 1985; 75(11): 1335–1337.